GSK 
Welcome,         Profile    Billing    Logout  
 323 Products   957 Diseases   323 Products   1268 Trials   64372 News 


«12...7891011121314151617...750751»
  • ||||||||||  Jemperli (dostarlimab-gxly) / GSK, Zejula (niraparib) / GSK, J&J
    Enrollment change, Trial completion date, Trial suspension, Trial primary completion date, Pan tumor:  NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov) -  Mar 26, 2024   
    P2,  N=51, Suspended, 
    N=112 --> 51 | Trial completion date: Mar 2027 --> Dec 2027 | Recruiting --> Suspended | Trial primary completion date: Mar 2024 --> Dec 2024
  • ||||||||||  Zejula (niraparib) / GSK, J&J
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  RiNG: Reirradiation and Niraparib in Patients With Recurrent Glioblastoma (clinicaltrials.gov) -  Mar 26, 2024   
    P1,  N=0, Withdrawn, 
    N=112 --> 51 | Trial completion date: Mar 2027 --> Dec 2027 | Recruiting --> Suspended | Trial primary completion date: Mar 2024 --> Dec 2024 N=15 --> 0 | Trial completion date: Jun 2025 --> Oct 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2024 --> Oct 2023
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Management of Vertebral Fragility Fracture in Older People: Recommendations from a Spanish Consensus of Experts. (Pubmed Central) -  Mar 25, 2024   
    Participants agreed on the administration of teriparatide for 24 months and then a switch to denosumab or bisphosphonates in patients at high risk of fracture...Although there was multidisciplinary agreement on diagnostic tests and non-pharmacological and pharmacological treatment in frail older people, therapeutic objectives should be individualized for every patient. In addition to the specific recommendations, close collaboration between the geriatrician and the primary care physician is essential for the optimal chronic management of frail patients with fragility fractures.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal, HEOR, Real-world evidence, Real-world:  Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis - real-world evidence from Germany. (Pubmed Central) -  Mar 25, 2024   
    Medication classification adhered to the German Society of Neurology guidelines and designated fumarates, glatiramer acetate, teriflunomide and interferons as low-efficacy category 1 medications; cladribine and S1P-modulators as medium-efficacy category 2 medications; and alemtuzumab, natalizumab, ocrelizumab, ofatumumab and rituximab (off-label) as high-efficacy category 3 medications...While most individuals started their treatment according to the treat-to-target approach and remained on their initially prescribed medication category, there has been a steadily increasing shift towards the EHT approach since 2020. These insights demonstrate that, while not officially recommended by German guidelines, MS providers increasingly adopt the EHT approach.
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Journal:  A Treatment Algorithm for High-Tone Pelvic Floor Dysfunction. (Pubmed Central) -  Mar 25, 2024   
    A stepwise approach to the treatment of HTPFD is recommended, with patients often necessitating multiple lines of treatment either sequentially or in conjunction. However, PFPT should be offered first line.
  • ||||||||||  GSK3036656 / GSK
    P2a data, Journal:  A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. (Pubmed Central) -  Mar 25, 2024   
    P2a
    GSK3036656 (ganfeborole) is a first-in-class benzoxaborole inhibiting the Mycobacterium tuberculosis leucyl-tRNA synthetase...Overall, 75 males were treated with ganfeborole (1/5/15/30?mg) or standard of care (Rifafour e-275 or generic alternative) once daily for 14?days...Analysis of whole-blood transcriptional treatment response to ganfeborole 30?mg at day 14 revealed a strong association with neutrophil-dominated transcriptional modules. The demonstrated bactericidal activity and acceptable safety profile suggest that ganfeborole is a potential candidate for combination treatment of pulmonary tuberculosis.ClinicalTrials.gov identifier: NCT03557281 .
  • ||||||||||  Journal:  Emerging biologic therapies for systemic lupus erythematosus. (Pubmed Central) -  Mar 25, 2024   
    EU Clinical Trials Register identifier 2015-003223-53 . While many drug candidates which met the end points in phase II trials have failed phase III trials, the number of target-specific therapies for SLE has continued to expand.
  • ||||||||||  Nucala (mepolizumab) / GSK, Xolair (omalizumab) / Roche, Novartis, Fasenra (benralizumab) / AstraZeneca
    Journal, HEOR:  Eosinophil to lymphocyte ratio may predict OCS reduction and change in quality of life (AQLQ) resulting from asthma biological treatment. (Pubmed Central) -  Mar 25, 2024   
    In the a/eos group there were significant correlations between initial ratio and age (r =0.36), and ACQ (r =-0.4) and ACQ (r =0.41) measured at the point 1. Pre-treatment eosinophil-to-lymphocyte ratio may predict oral corticosteroid dose reduction resulting from omalizumab treatment and change in quality of life and asthma control resulting from anti-IL-5 and IL-5R treatment.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Enrollment closed:  CAPRI: A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA (clinicaltrials.gov) -  Mar 25, 2024   
    P3,  N=12, Active, not recruiting, 
    Pre-treatment eosinophil-to-lymphocyte ratio may predict oral corticosteroid dose reduction resulting from omalizumab treatment and change in quality of life and asthma control resulting from anti-IL-5 and IL-5R treatment. Recruiting --> Active, not recruiting
  • ||||||||||  Journal:  Application of biologicals in patients with food allergies (Pubmed Central) -  Mar 24, 2024   
    Antibodies against alarmins and anti-IL-5, such as etokimab and mepolizumab, have proven efficacy in preclinical studies and clinical trials. While further studies are needed to establish their practical clinical use and determine suitability for different types of food allergies, these monoclonal antibodies present a promising horizon for the treatment of such conditions.
  • ||||||||||  cinacalcet HCl / Generic mfg.
    Nephrogenic Diabetes Insipidus secondary to Hypercalcemia of Malignancy responsive to Cinacalcet () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_541;    
    Ionized calcium remained the same despite Zometa, calcitonin, denosumab, and aggressive IVF with NS...Desmopressin was then initiated but did not sufficiently concentrate the urine... This case exhibits the potential use of cinacalcet for the treatment of nephrogenic DI secondary to hypercalcemia of malignancy.
  • ||||||||||  Benlysta (belimumab) / GSK, Lupkynis (voclosporin) / Aurinia Pharma
    Successful Treatment of Lupus Nephritis with Belimumab and Voclosporin: A Rare Case () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_520;    
    This case highlights the significant positive response achieved through the combination of Belimumab and Voclosporin, along with low-dose steroids, without any significant adverse effects. Further research is warranted to assess the safety and efficacy of combining Belimumab and Voclosporin in the management of LN.
  • ||||||||||  Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) / Merck (MSD)
    Repurposing varicella zoster virus and human papillomavirus vaccines for local immunotherapy against solid tumors (Room W175) -  Mar 22, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_417;    
    Finally, IT injection of Shingrix and the E7 viral neoantigen peptide led to the eradication of all primary injected and abscopal tumors. Our results indicate that Shingrix is a versatile component for in-situ vaccination which can be combined with peptides derived from licensed vaccines or tumor antigens.
  • ||||||||||  vistusertib (AZD2014) / AstraZeneca, ZM 447439 - Bio / Techne, CZC24832 / GSK
    Journal, Tumor mutational burden, Machine learning:  The cell death-related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinoma. (Pubmed Central) -  Mar 22, 2024   
    Conversely, for the high-risk group patients, PD173074, ZM447439 and CZC24832 exhibit a stronger response...This innovative model provides a novel approach for forecasting prognosis and assessing drug sensitivity in HCC patients, driving a more personalized and efficacious treatment paradigm, elevating clinical outcomes. Nonetheless, additional research endeavours are required to confirm the model's precision and assess its potential to inform clinical decision-making for HCC patients.
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Journal:  Factors Associated With Onabotulinum Toxin-A Discontinuation in a Diverse Urban Population. (Pubmed Central) -  Mar 22, 2024   
    Patients who reported nocturia and UUI before injection were more likely to continue BTX-A suggesting more severe OAB is more responsive to this therapy. Given the large proportion (>40%) of patients who discontinued BTX-A treatment, further research is needed to identify barriers to continuation of care.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy:  STOMP: Selinexor and Backbone Treatments of Multiple Myeloma Patients (clinicaltrials.gov) -  Mar 22, 2024   
    P1/2,  N=300, Active, not recruiting, 
    The A. dracunculus aqueous extract exhibited potent DPPH free radical inhibitory (IC50 dose of 10.71 Phase classification: P1b/2 --> P1/2 | N=518 --> 300 | Trial completion date: Jan 2025 --> Apr 2027 | Trial primary completion date: Jan 2025 --> Apr 2027